Washington, D.C. (July 17, 2017) – The Biotechnology Innovation Organization (BIO) today issued the following statement on the status of the U.S.-China 100-day plan:
“The Biotechnology Innovation Organization remains focused on achieving full success as part of the U.S.-China 100-day plan. To date, the Chinese Ministry of Agriculture has approved four of the eight products identified as part of the “Initial Results of the 100-day Action Plan,” released on May 11, 2017. This agreement established a process to ensure that the Chinese National Biosafety Committee (NBC) and Ministry of Agriculture (MOA) could satisfy any remaining technical questions related to the intended use of the products in a timely manner and to hold NBC meetings as frequently and as soon as possible to finalize the reviews.
“As the U.S. and Chinese governments meet this week as part of the U.S.-China Comprehensive Economic Dialogue, industry urges the governments to provide additional clarity regarding the implementation of this agreement to ensure that the process is completed and all eight products are approved without delay. On average, the eight products have been pending Chinese approval for five years and already have been approved in multiple markets around the world.”
About BIO
BIO is the premier biotechnology advocacy organization representing biotech companies, industry leaders, and state biotech associations in the United States and more than 35 countries around the globe. BIO members range from biotech start-ups to some of the world’s largest biopharmaceutical companies – all united by the same goal: to develop medical and scientific breakthroughs that prevent and fight disease, restore health, and improve patients’ lives. BIO also organizes the BIO International Convention and a series of annual conferences that drive partnerships, investment, and progress within the sector. Learn more at bio.org.
Upcoming BIO Events
BIO World Congress on Industrial Biotechnology
July 23 - 26, 2017
Montréal, Canada